Global Omeprazole Market
Market Size in USD Billion
USD
3.28 Billion
USD
4.28 Billion
2025
2033
Forecast Period |
2026 - 2033 |
Market Size (Base Year) |
USD 3.28 Billion |
Market Size (Forecast Year) |
USD 4.28 Billion |
CAGR |
% |
Major Markets Players |
|
Forecast Period
Market Size (Base Year)
Market Size (Forecast Year)
CAGRWhat is the Omeprazole Market Size and Growth Rate?
- As per Data Bridge Market Research analysis the omeprazole market was valued at USD 3.28 billion in 2025 and is projected to reach USD 4.28 billion by 2033, growing at a CAGR of 3.40% from 2026 to 2033.
- The market is experiencing steady growth driven by the increasing prevalence of gastroesophageal reflux disease (GERD), peptic ulcers, and acid-related gastrointestinal disorders, along with rising demand for effective proton pump inhibitor (PPI) therapies across hospital and retail healthcare settings.
- The growing aging population, increasing use of non-steroidal anti-inflammatory drugs (NSAIDs), and expanding access to generic pharmaceutical products are encouraging healthcare providers to prescribe omeprazole for long-term acid suppression and ulcer prevention, supporting continued market expansion.
Market Size & Forecast
- Market Value (2025): USD 3.28 Billion
- Expected Market Value (2033): USD 4.28 Billion
- Forecast CAGR (2026–2033): 3.40%
- Leading Region in 2025: North America
- Fastest Growing Region: Asia-Pacific
What are the Major Takeaways of the Omeprazole Market?
- North America dominated the omeprazole market in 2025, supported by the high prevalence of gastroesophageal reflux disease (GERD), peptic ulcers, and other acid-related gastrointestinal disorders, along with strong awareness regarding early diagnosis and treatment.
- Asia-Pacific omeprazole market is expected to witness the fastest growth rate from 2026 to 2033, supported by rising prevalence of gastric disorders, expanding healthcare infrastructure, and increasing healthcare expenditure across countries such as China, Japan, and India.
- The capsule segment held the largest market revenue share in 2025 driven by its widespread prescription for the treatment of acid-related gastrointestinal disorders and its availability in both branded and generic formulations. Capsules are preferred due to their delayed-release properties, ease of administration, and consistent therapeutic effectiveness in reducing gastric acid secretion.
- The tablet segment is projected to register the fastest growth from 2026 to 2033, driven by increasing demand for convenient oral dosage forms, expanding availability of over-the-counter products, and growing adoption of generic medications across developed and emerging markets.
- The gastroesophageal reflux disease (GERD) segment held the largest market revenue share in 2025 driven by the rising prevalence of acid reflux disorders, increasing awareness of gastrointestinal health, and growing long-term use of proton pump inhibitors. Omeprazole remains one of the most commonly prescribed therapies for effective GERD management.
- The erosive esophagitis segment is projected to register the fastest growth from 2026 to 2033, driven by increasing diagnosis rates, improved access to gastrointestinal healthcare services, and growing adoption of long-term acid suppression therapies.
Report Scope and Omeprazole Market Segmentation
|
Attributes |
Omeprazole Key Market Insights |
|
Segments Covered |
|
|
Countries Covered |
North America
Europe
Asia-Pacific
Middle East and Africa
South America
|
|
Key Market Players |
|
|
Market Opportunities |
|
|
Value Added Data Infosets |
In addition to the insights on market scenarios such as market value, growth rate, segmentation, geographical coverage, and major players, the market reports curated by the Data Bridge Market Research also include depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework. |
What is the Key Trend in the Omeprazole Market?
- Pharmaceutical manufacturers are increasingly focusing on developing patient-friendly formulations and expanding over-the-counter availability of omeprazole to improve treatment accessibility for acid-related gastrointestinal disorders while enhancing patient compliance.
- For instance, in April 2024, Haleon expanded the availability of Prilosec OTC across major retail channels, reinforcing its commitment to providing convenient self-care solutions for frequent heartburn sufferers.
- Drug manufacturers are also investing in improved delayed-release formulations, combination therapies, and expanded distribution networks to strengthen gastrointestinal treatment options across both prescription and OTC markets.
- For instance, in 2024, Viatris continued strengthening its global portfolio of generic gastrointestinal medicines, including omeprazole formulations, to improve patient access to affordable proton pump inhibitor therapies across multiple international markets.
- As healthcare systems increasingly emphasize affordable gastrointestinal care and self-medication for common acid-related disorders, the adoption of omeprazole is expected to accelerate, reinforcing its position as one of the most widely used proton pump inhibitors globally.
What are the Key Drivers of the Omeprazole Market?
- The increasing prevalence of gastroesophageal reflux disease (GERD), peptic ulcers, Zollinger-Ellison syndrome, and other acid-related gastrointestinal disorders has significantly increased demand for omeprazole across hospitals, clinics, and retail pharmacies.
- For instance, in 2024, AstraZeneca continued supporting clinical education and patient awareness initiatives related to gastrointestinal disease management, reinforcing the long-standing clinical importance of proton pump inhibitors such as omeprazole.
- Pharmaceutical companies are expanding generic drug production and improving supply chain capabilities to increase affordability and ensure consistent availability of omeprazole across developed and emerging healthcare markets.
- For instance, in 2024, Dr. Reddy's Laboratories continued expanding its portfolio of affordable generic medicines, including gastrointestinal therapies, to improve patient access across global markets.
- With the growing burden of digestive disorders, increasing aging population, and expanding access to cost-effective generic medicines, omeprazole is expected to remain a cornerstone therapy for long-term gastric acid suppression and ulcer management.
Which Factors are Challenging the Growth of the Omeprazole Market?
- Long-term use of omeprazole has raised concerns regarding potential adverse effects, including nutrient deficiencies, kidney-related complications, and increased risk of certain infections, leading to cautious prescribing practices.
- Increasing regulatory scrutiny, growing preference for alternative treatment approaches, and competition from other proton pump inhibitors and acid-suppressing therapies continue to challenge market expansion.
- For instance, in 2024, the U.S. Food and Drug Administration (FDA) continued to advise healthcare professionals and patients to use proton pump inhibitors according to approved labeling and recommended treatment durations to minimize potential long-term safety risks.
- Safety concerns associated with prolonged therapy, combined with increasing generic competition, pricing pressure, and evolving treatment guidelines, continue to limit market growth despite the widespread clinical use of omeprazole for acid-related gastrointestinal disorders.
How is the Omeprazole Market Segmented?
The market is segmented on the basis of dosage form, indication, and distribution channel.
- By Dosage Form
On the basis of dosage form, the omeprazole market is segmented into capsule, powder, and tablet. The capsule segment held the largest market revenue share in 2025 driven by its widespread prescription for the treatment of acid-related gastrointestinal disorders and its availability in both branded and generic formulations. Capsules are preferred due to their delayed-release properties, ease of administration, and consistent therapeutic effectiveness in reducing gastric acid secretion.
The tablet segment is projected to register the fastest growth from 2026 to 2033, driven by increasing demand for convenient oral dosage forms, expanding availability of over-the-counter products, and growing adoption of generic medications across developed and emerging markets.
- By Indication
On the basis of indication, the omeprazole market is segmented into duodenal ulcer, gastric ulcer, gastroesophageal reflux disease (GERD), erosive esophagitis, and others. The gastroesophageal reflux disease (GERD) segment held the largest market revenue share in 2025 driven by the rising prevalence of acid reflux disorders, increasing awareness of gastrointestinal health, and growing long-term use of proton pump inhibitors. Omeprazole remains one of the most commonly prescribed therapies for effective GERD management.
The erosive esophagitis segment is projected to register the fastest growth from 2026 to 2033, driven by increasing diagnosis rates, improved access to gastrointestinal healthcare services, and growing adoption of long-term acid suppression therapies.
- By Distribution Channel
On the basis of distribution channel, the omeprazole market is segmented into hospital pharmacies, retail pharmacies, and online pharmacies. The retail pharmacies segment held the largest market revenue share in 2025 driven by widespread availability of prescription and over-the-counter omeprazole products, strong consumer accessibility, and the growing use of generic formulations. Retail pharmacies continue to be the preferred purchasing channel for patients managing chronic acid-related disorders.
The online pharmacies segment is projected to register the fastest growth from 2026 to 2033, driven by increasing adoption of digital healthcare platforms, expanding e-commerce pharmaceutical services, and growing consumer preference for convenient home delivery of prescription and OTC medications.
Which Region Holds the Largest Share of the Omeprazole Market?
- North America dominated the omeprazole market in 2025, supported by the high prevalence of gastroesophageal reflux disease (GERD), peptic ulcers, and other acid-related gastrointestinal disorders, along with strong awareness regarding early diagnosis and treatment.
- The widespread availability of prescription and over-the-counter omeprazole products, well-established healthcare infrastructure, and favorable reimbursement policies continue to drive market growth. This widespread adoption is further supported by an aging population and increasing use of proton pump inhibitors for long-term acid suppression therapy.
U.S. Omeprazole Market Insight
U.S. omeprazole market captured the largest market share in 2025 within North America, fueled by the rising incidence of acid reflux disorders and increasing demand for affordable generic gastrointestinal medicines. Healthcare providers continue to prescribe omeprazole extensively for GERD, gastric ulcers, and NSAID-induced ulcers. Moreover, the widespread availability of OTC formulations through retail and online pharmacies is significantly contributing to market expansion.
Europe Omeprazole Market Insight
Europe omeprazole market is expected to witness the fastest growth rate from 2026 to 2033, primarily driven by the increasing prevalence of digestive disorders, expanding geriatric population, and growing awareness regarding gastrointestinal health. Rising demand for cost-effective generic proton pump inhibitors and improved access to healthcare services are fostering market growth. The region is also experiencing increased adoption of preventive gastrointestinal therapies across hospitals and outpatient care settings.
U.K. Omeprazole Market Insight
U.K. omeprazole market is expected to witness the fastest growth rate from 2026 to 2033, driven by increasing diagnosis of acid-related gastrointestinal diseases and growing utilization of proton pump inhibitors in primary healthcare. In addition, the widespread availability of generic omeprazole through the National Health Service (NHS) and retail pharmacies is expected to continue stimulating market growth.
Germany Omeprazole Market Insight
Germany omeprazole market is expected to witness the fastest growth rate from 2026 to 2033, fueled by increasing awareness of gastrointestinal disease management and strong demand for effective acid suppression therapies. Germany's advanced healthcare infrastructure, combined with extensive use of generic pharmaceuticals and growing emphasis on preventive healthcare, continues to promote the adoption of omeprazole across hospital and outpatient settings.
Asia-Pacific Omeprazole Market Insight
The Asia-Pacific omeprazole market is expected to witness the fastest growth rate from 2026 to 2033, supported by rising prevalence of gastric disorders, expanding healthcare infrastructure, and increasing healthcare expenditure across countries such as China, Japan, and India. The region's growing access to affordable generic medicines and increasing awareness regarding digestive health are driving the adoption of omeprazole. Furthermore, the expansion of pharmaceutical manufacturing and distribution networks is improving product accessibility across both urban and rural populations.
Japan Omeprazole Market Insight
Japan omeprazole market is expected to witness the fastest growth rate from 2026 to 2033 due to the country's aging population, increasing prevalence of gastrointestinal disorders, and strong emphasis on early disease diagnosis and treatment. The growing adoption of advanced healthcare services and effective proton pump inhibitor therapies continues to support market growth. Moreover, increasing demand for long-term management of chronic digestive disorders is driving omeprazole utilization across healthcare facilities.
China Omeprazole Market Insight
The China omeprazole market accounted for the largest market share in Asia-Pacific in 2025, attributed to the country's large patient population, increasing prevalence of gastrointestinal diseases, and expanding access to affordable healthcare services. China remains one of the largest producers and consumers of generic pharmaceuticals, with omeprazole widely prescribed for GERD, peptic ulcers, and other acid-related disorders. Growing healthcare investments and expanding pharmaceutical manufacturing capabilities continue to propel market growth across the country.
Which are the Top Companies in Omeprazole Market?
The omeprazole industry is primarily led by well-established companies, including:
- AstraZeneca PLC (U.K.)
- Viatris Inc. (U.S.)
- Sandoz Group AG (Switzerland)
- Dr. Reddy's Laboratories Ltd. (India)
- Teva Pharmaceutical Industries Ltd. (Israel)
- Sun Pharmaceutical Industries Ltd. (India)
- Apotex Inc. (Canada)
- Perrigo Company plc (Ireland)
- Hikma Pharmaceuticals PLC (U.K.)
- Aurobindo Pharma Limited (India)
- Lupin Limited (India)
- Cipla Limited (India)
- Zydus Lifesciences Limited (India)
- Torrent Pharmaceuticals Ltd. (India)
- Glenmark Pharmaceuticals Ltd. (India)
SKU-
- Interactive Data Analysis Dashboard
- Company Analysis Dashboard for high growth potential opportunities
- Research Analyst Access for customization & queries
- Competitor Analysis with Interactive dashboard
- Latest News, Updates & Trend analysis
- Harness the Power of Benchmark Analysis for Comprehensive Competitor Tracking
Data collection and base year analysis are done using data collection modules with large sample sizes. The stage includes obtaining market information or related data through various sources and strategies. It includes examining and planning all the data acquired from the past in advance. It likewise envelops the examination of information inconsistencies seen across different information sources. The market data is analysed and estimated using market statistical and coherent models. Also, market share analysis and key trend analysis are the major success factors in the market report. To know more, please request an analyst call or drop down your inquiry.
The key research methodology used by DBMR research team is data triangulation which involves data mining, analysis of the impact of data variables on the market and primary (industry expert) validation. Data models include Vendor Positioning Grid, Market Time Line Analysis, Market Overview and Guide, Company Positioning Grid, Patent Analysis, Pricing Analysis, Company Market Share Analysis, Standards of Measurement, Global versus Regional and Vendor Share Analysis. To know more about the research methodology, drop in an inquiry to speak to our industry experts.
Data Bridge Market Research is a leader in advanced formative research. We take pride in servicing our existing and new customers with data and analysis that match and suits their goal. The report can be customized to include price trend analysis of target brands understanding the market for additional countries (ask for the list of countries), clinical trial results data, literature review, refurbished market and product base analysis. Market analysis of target competitors can be analyzed from technology-based analysis to market portfolio strategies. We can add as many competitors that you require data about in the format and data style you are looking for. Our team of analysts can also provide you data in crude raw excel files pivot tables (Fact book) or can assist you in creating presentations from the data sets available in the report.
